GC Corp. bought ARTV
May 11, 2026 · Form 4 insider transaction
GC Corp. bought 347,222 shares of Artiva Biotherapeutics, Inc. at $11.52 per share, a transaction worth $4.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 17 days after the transaction.
Footnotes
The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.